Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T21:08:06.334Z.
Calculation as of: 2026-10-06T21:08:06.334Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4553d85706fed5bac33927ddb0c45062b9ca990621471d16f8faa1ad8920ffc8
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$159.80M
EV/Sales Ratio
N/A
TTM Avg
2.01x
3Y Avg
2.01x
5Y Avg
2.01x
Market Cap
$159.14M
EV/Sales Ratio
2.24x
TTM Avg
2.39x
3Y Avg
2.07x
5Y Avg
2.67x
Market Cap
$162.04M
EV/Sales Ratio
0.99x
TTM Avg
1.48x
3Y Avg
2.94x
5Y Avg
3.59x
Market Cap
$165.27M
EV/Sales Ratio
N/A
TTM Avg
2761537.75x
3Y Avg
2761537.75x
5Y Avg
2761537.75x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PepGen Inc. (PEPG) | $159.78M | N/A | N/A | N/A | N/A |
| Minerva Neurosciences, Inc. (NERV)vs › | $159.80M | N/A | 2.01x | 2.01x | 2.01x |
| LifeMD, Inc. (LFMDP)vs › | $159.22M | 0.69x | 4.59x | 4.77x | 4.78x |
| Coherus Oncology, Inc. (CHRS)vs › | $159.14M | 2.24x | 2.39x | 2.07x | 2.67x |
| Quanterix Corporation (QTRX)vs › | $162.04M | 0.99x | 1.48x | 2.94x | 3.59x |
| Inogen, Inc. (INGN)vs › | $156.22M | 0.24x | 0.27x | 0.30x | 0.57x |
| Nkarta, Inc. (NKTX)vs › | $165.27M | N/A | 2761537.75x | 2761537.75x | 2761537.75x |
| OptimizeRx Corp. (OPRX)vs › | $165.32M | 1.63x | 1.75x | 2.23x | 4.49x |
| Neuronetics, Inc. (STIM)vs › | $153.79M | 1.43x | 1.39x | 1.55x | 1.31x |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $153.58M | N/A | N/A | N/A | N/A |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
